Atrys makes the leap to the Continuous Market with the aim of incorporating international equity funds into its shareholding. On Monday, February 7th, the shares that make up the stock capital of Atrys Health, listed on BME Growth, will be traded on the stock exchange, following the approval by the Spanish securities market supervisor (CNMV). The shares will be traded under the code “ATRY”.
The share’s closing price on BME Growth today, February 4th, will be used as the reference price for the start of trading. The opening auction will begin at 8:30 am on Monday and will end at 12:00 pm, following the shares’ admission to trading.
Atrys Health was listed on BME Growth in July 2016 and has carried out several capital increase transactions which have paved the way for its international expansion. It has also relied on BME’s Fixed Income market, MARF, to diversify its financing sources via bond issuance programmes. The company, which specialises in innovative oncology diagnosis and treatment services, is the third one to move from the SME Growth market to the stock exchange, following MásMóvil and Grenergy.
“This is a clear example of how companies can increase their size significantly by building upon the recurring funding they receive as they tap the capital markets,”Beatriz Alonso-Majagranzas, head of BME Exchange
Atrys is currently listed on the BME Growth with a market capitalisation of €600 million. It is a global company that provides precision medical diagnosis and treatment services, pioneer in telemedicine and state-of-the-art radiotherapy. In terms of revenue, its turnover has grown from €4.5 million in 2016 to a pro forma turnover of more than €85 million in the first half of 2021 alone. And in the same period of just 6 years, it has grown from a team of 44 professionals to more than 2,000 today.
“With the confirmation from the CNMV that we meet all the necessary requirements to be admitted for trading our shares on the Madrid, Barcelona, Bilbao and Valencia stock exchanges, we are closing the first stage of our trajectory and beginning a new chapter in the main market where we will seek to provide more liquidity to the share, bring in new national and international investors and drive our organic and inorganic growth plan.”Santiago de Torres, Chairman of Atrys
Gómez-Acebo & Pombo advised Atrys Health wit a Corporate team led by partner and co-coordinator of the Capital Markets practice Guillermo Guerra, and integrated by associate Jacobo Palanca, paralegal Irene Carreño Uría, along with Banking paralegal Irene Medina.